Brain Cancer Patient Articles & Analysis
17 news found
“Together with leading neuro-oncologists and computational biologists, we are bringing evidence-based insights to the treatment of brain cancer patients.” The xCures platform generates Real-time, Regulatory-grade, Clinical data (RRC). It now includes data on over 1,000 brain cancer ...
ByxCures
The study population in the dose escalation phase will include patients with stable brain metastasis whose disease has failed prior standard therapy. ...
“The molecular heterogeneity of GBM is a key driver for the inconsistent therapy response rates that we see in brain cancer patients and makes the disease difficult to treat,” said Patrick Wen, MD, Director, Center for Neuro-oncology, Dana-Farber Cancer Institute; Professor, Neurology, Harvard Medical School; and ...
Secondary endpoints included pharmacokinetic measurement of TSC levels after dosing, relative improvements in blood oxygen levels, and certain other clinical parameters related to COVID-19. In this trial, patients were divided into four sequential cohorts of six patients, with each patient in a dose cohort receiving the same intravenous doses of ...
ByCervoMed
In the Toxicity Atlas project, Medstoner Silvia Scoarta, VUmc professor Bart Westerman, and their team are researching better ways to treat brain cancer. Quite the task! Ghislaine’s expertise in biology and bio-informatics will make a great contribution to the project by, among other things, calculating predictions based on (clinical) data. Her work will ...
His tumor recurrence was a single brain lesion, and the patient had a good performance status with the ability to undergo repeat surgery as well as radiation,” said Dr. ...
(Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their ...
Nearly 24,530 patients will be diagnosed with brain or other nervous system cancers in 2021 within the United States1, and for many of these patients, especially those with recurrent, metastatic, or rare disease, a treatment path is not clear. Functional drug screening of patient-derived tumor models is being ...
Mehee Choi, director of Medical Affairs at GT Medical Technologies, will discuss new data in patients with recurrent glioblastoma (GBM), and access-to-care for patients with resectable brain tumors. ...
“We chose them because their technologies solve important patient needs and have great market potential, and we think their teams can get the job done. ...
"We chose them because their technologies solve important patient needs and have great market potential, and we think their teams can get the job done. ...
University Hospitals Seidman Cancer Center is the first to offer this to patients with brain tumors in Cleveland. ...
University Hospitals Seidman Cancer Center is the first to offer this to patients with brain tumors in Cleveland. ...
GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumors. ...
A new imaging technique and artificial intelligence (AI) are poised to significantly advance what neurosurgeons can do to help patients with brain tumors while they’re on the operating room table. ...
"We are excited about the potential of LAUR-401. Many anti-cancer agents have shown potential for GBM, but, since they can neither cross the brain, by existing oral or i.v. administration, nor target GBM cells, they fall short for patients. This challenge represents a critical unmet medical need for brain cancer ...
"VABC's grant is recognition of our successes to date, and investment in the future success of V-Smart™ for GBM as a transformative therapeutic for brain cancer patients." "A major goal of VABC is to invest in cutting edge developments that can have a monumental impact on the course of brain cancer," said ...